Xeljanz®

(Tofacitinib)

PATIENT SAFETY CARD

PATIENT SAFETY CARD

The Patient Safety Card will be manufactured on a durable, portable, convenient-sized medium.

XELJANZ PATIENT SAFETY CARD
(tofacitinib)

- This card contains important safety information that you need to be aware of before you start taking XELJANZ and during your treatment with XELJANZ. If you do not understand this information, please ask your doctor/pharmacist to explain it to you.
- Keep this card with you and show it to any doctor or pharmacist involved in your care.
- See the XELJANZ package leaflet for more information.

Tell your doctor or your pharmacist about ALL the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements.

XELJANZ is not recommended for use with biologic DMARDs for rheumatoid arthritis or with certain other medicines that depress your immune system (e.g., azathioprine, tacrolimus, cyclosporine or mycophenolate). Taking XELJANZ with these medicines may increase your risk of infection.

During treatment with XELJANZ

Tell your doctor **immediately** if you:

- Develop symptoms of an infection, such as fever, persistent cough, weight loss, or excessive tiredness. XELJANZ may increase your risk of getting infections, which can become serious if not treated. You may be at higher risk for infections if you are 65 years of age or older, have diabetes, chronic lung disease, or are taking corticosteroids. Your XELJANZ treatment may be stopped by your doctor.
- Have been in close contact with a person with tuberculosis.
- Develop abdominal signs and symptoms such as stomach pain, abdominal pain, blood in your stool, or any change in your bowel habits with fever.
- Develop yellow skin, nausea or vomiting.
- Are due to receive any vaccine. You should not receive certain types of vaccines while taking XELJANZ.
- Become pregnant or plan on becoming pregnant. XELJANZ should not be used during pregnancy unless clearly necessary. Women of childbearing potential should be advised to use effective contraception during treatment with XELJANZ and for at least 4 weeks after the last dose. Women should not breast-feed while being treated with XELJANZ.

Seek **immediate** medical attention and stop taking XELJANZ until you discuss with your doctor:

- Experience possible symptoms of allergic reactions such as chest tightness, wheezing, severe dizziness or light-headedness, swelling of the lips, tongue or throat, itching or skin rash when taking XELJANZ, or soon after taking XELJANZ

Other Information (please complete)

Patient's Name: _____

Doctor's Name: _____

Doctor's Phone: _____

Doctor's Fax:_____

Hospital Name: _____

Hospital Phone: _____

XELJANZ Treatmet Start Date: _____

If you stop taking XELJANZ, keep this card with you for at least 2 months after taking the last dose of XELJANZ.

Please report any adverse events through the following channels

1. The National Pharmacovigilance & Drug Safety Centre (NPC)
Fax: +966 112057662
The unified Number: 19999
Toll free phone: 8002490000
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc

Or

2. The Pharmacovigilance Department in Pfizer:
Email: SAU.AEReporting@Pfizer.com
Tel.: 012 22 93 633